Llwytho...
Best Practices for Preclinical In Vivo Testing of Cancer Nanomedicines
Significant advances have been made in the design, discovery, and development of nanoparticles for cancer treatment in recent years. However, despite promising results in preclinical animal models, cancer nanomedicines often fail in clinical trials during phase II and phase III testing due to lack o...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Adv Healthc Mater |
|---|---|
| Prif Awduron: | , , , , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2020
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7473451/ https://ncbi.nlm.nih.gov/pubmed/32367687 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adhm.202000110 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|